Induction of Protective Serum Meningococcal Bactericidal and Diphtheria-Neutralizing Antibodies and Mucosal Immunoglobulin A in Volunteers by Nasal Insufflations of the Neisseria meningitidis Serogroup C Polysaccharide-CRM197 Conjugate Vaccine Mixed with Chitosan

ABSTRACT Thirty-six healthy volunteers received either a single intramuscular injection of Neisseria meningitidis serogroup C polysaccharide (MCP)-CRM197 conjugate vaccine in alum or two nasal insufflations 28 days apart of the same vaccine powder, without alum, mixed with chitosan. Nasal immunization was well tolerated, with fewer symptoms reported than after intramuscular injection. The geometric mean concentrations of MCP-specific immunoglobulin G (IgG) after one nasal immunization were 3.25 μg/ml in naïve subjects and 14.4 μg/ml in subjects previously immunized parenterally, compared with 4.30 μg/ml in naïve subjects immunized intramuscularly. The geometric mean titer of serum bactericidal antibody (SBA) rose 24-fold after two nasal immunizations in naïve subjects and was comparable to parenteral immunization (1,080 versus 1,625). All subjects achieved SBA titers associated with protection after two nasal immunizations: even those with titers of <8 at entry. A single nasal immunization boosted the SBA titer to ≥128 in 96% of previously immunized subjects, and two immunizations achieved this level in 92% of naive subjects. MCP-specific IgG levels were ∼70% IgG2 and ∼20% IgG1 after nasal or intramuscular immunization. Increases in CRM197-specific IgG and diphtheria toxin-neutralizing activity were observed after nasal or intramuscular immunization, with balanced IgG1/IgG2 and higher IgG4. Significant MCP-specific secretory IgA was detected in nasal wash only after nasal immunization and predominantly on the immunized side. Simple nasal insufflation of existing MCP-CRM197 conjugate vaccines in chitosan offers an inexpensive but effective needle-free prime and boost against serogroup C N. meningitidis and diphtheria.

[1]  F. Mahoney,et al.  The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt. , 2005, Vaccine.

[2]  E. Miller,et al.  Meningococcal surrogates of protection--serum bactericidal antibody activity. , 2005, Vaccine.

[3]  G. Kraal Chapter 23 – Nasal-Associated Lymphoid Tissue , 2005 .

[4]  Elizabeth Miller,et al.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction , 2004, The Lancet.

[5]  S. Clare,et al.  Mucosal Vaccination against Serogroup B Meningococci: Induction of Bactericidal Antibodies and Cellular Immunity following Intranasal Immunization with NadA of Neisseria meningitidis and Mutants of Escherichia coli Heat-Labile Enterotoxin , 2004, Infection and Immunity.

[6]  A. Meyerhans,et al.  Gut-homing (α4β7+) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors , 2004 .

[7]  R. Rappuoli,et al.  Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. , 2004, The Journal of infectious diseases.

[8]  R. Borrow,et al.  Assignment of Neisseria meningitidis Serogroups A, C, W135, and Y Anticapsular Total Immunoglobulin G (IgG), IgG1, and IgG2 Concentrations to Reference Sera , 2004, Clinical Diagnostic Laboratory Immunology.

[9]  A. Meyerhans,et al.  Gut-homing (alpha(4)beta(7)(+)) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors. , 2004, The Journal of general virology.

[10]  N. Andrews,et al.  Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England , 2003, Clinical Diagnostic Laboratory Immunology.

[11]  F. Oftung,et al.  Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. , 2003, Vaccine.

[12]  R. Rappuoli,et al.  Protective Levels of Diphtheria-Neutralizing Antibody Induced in Healthy Volunteers by Unilateral Priming-Boosting Intranasal Immunization Associated with Restricted Ipsilateral Mucosal Secretory Immunoglobulin A , 2003, Infection and Immunity.

[13]  E. Miller,et al.  Impact of meningococcal C conjugate vaccine in the UK. , 2002, Journal of medical microbiology.

[14]  P. Riches,et al.  Limitations of Pneumovax® as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay , 2002, Annals of clinical biochemistry.

[15]  B. Brandt,et al.  Immunogenicity and Safety Testing of a Group B Intranasal Meningococcal Native Outer Membrane Vesicle Vaccine , 2002, Infection and Immunity.

[16]  D. Goldblatt,et al.  Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. , 2002, The Journal of infectious diseases.

[17]  David N. Taylor,et al.  Safety and Immunogenicity of a Proteosome-Shigella flexneri 2a Lipopolysaccharide Vaccine Administered Intranasally to Healthy Adults , 2001, Infection and Immunity.

[18]  H. Domdey,et al.  Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. , 2001, Vaccine.

[19]  R. Rappuoli,et al.  A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. , 2000, Vaccine.

[20]  M. Roberts,et al.  Carbohydrate Biopolymers Enhance Antibody Responses to Mucosally Delivered Vaccine Antigens , 2000, Infection and Immunity.

[21]  F. Oftung,et al.  Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. , 2000, Vaccine.

[22]  F. Oftung,et al.  A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. , 2000, Journal of medical microbiology.

[23]  G. Carlone,et al.  Elderly immune response to a TI-2 antigen: heavy and light chain use and bactericidal activity to Neisseria meningitidis serogroup C polysaccharide. , 1999, The Journal of infectious diseases.

[24]  F. Oftung,et al.  Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. , 1999, Vaccine.

[25]  A. Perkins,et al.  Evaluation of the clearance characteristics of bioadhesive systems in humans. , 1999, International journal of pharmaceutics.

[26]  J. Chippaux,et al.  Meningococcal immunisation and protection from epidemics , 1998, The Lancet.

[27]  J. Holmgren,et al.  Differential Kinetics and Distribution of Antibodies in Serum and Nasal and Vaginal Secretions after Nasal and Oral Vaccination of Humans , 1998, Infection and Immunity.

[28]  F. Oftung,et al.  Intranasal Administration of a Meningococcal Outer Membrane Vesicle Vaccine Induces Persistent Local Mucosal Antibodies and Serum Antibodies with Strong Bactericidal Activity in Humans , 1998, Infection and Immunity.

[29]  J. Holmgren,et al.  Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina , 1997, Infection and immunity.

[30]  J. Lowe,et al.  Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. , 1997, Journal of pharmaceutical sciences.

[31]  S. Gizurarson,et al.  Intranasal booster vaccination against diphtheria and tetanus in man. , 1997, Vaccine.

[32]  E. Tikhomirov,et al.  Meningococcal disease: public health burden and control. , 1997, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[33]  C. Czerkinsky,et al.  Induction of compartmentalized B-cell responses in human tonsils , 1995, Infection and immunity.

[34]  J. Biewenga,et al.  The role of nasopharyngeal lymphoid tissue. , 1992, Immunology today.

[35]  M. Corbel,et al.  Human antibody response to fragments A and B of diphtheria toxin and a synthetic peptide of amino acid residues 141–157 of fragment A , 1990, Epidemiology and Infection.

[36]  J. Mcghee,et al.  Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses. , 1990, Journal of immunology.

[37]  K. Miyamura,et al.  Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. II. Comparison with the rabbit skin method and practical application for seroepidemiological studies. , 1974, Journal of biological standardization.

[38]  K. Miyamura,et al.  Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration. , 1974, Journal of biological standardization.